My ePortfolio Register   

ASCO 2010: Breast cancers spread to the liver may change biology, impacting treatment effectiveness

A retrospective study of women with metastatic breast cancer shows that the biological characteristics of their primary tumours – including oestrogen, progesterone, and HER2 status – often changes when cancer spread to the liver, requiring a change in therapy in more than 12 percent of patients.

“These results indicate that tumour biology often changes between primary and metastatic lesions, and suggest that biopsies of these secondary tumours should be performed whenever feasible,” said co-author Giuseppe Curigliano, MD, PhD, senior deputy director in the division of medical oncology at the
European Institute of Oncology in Milan, Italy. “Traditionally, we start therapy according to the biological features of the primary tumour, and these results can influence treatment choices as many as 10 years later. Retesting secondary tumours will help us ensure that patients get the most effective therapy
possible, which can have a dramatic impact on their overall outcome.”

The choice of therapy for women with breast cancer is based on the status of key biological markers, such as oestrogen and progesterone receptors and HER2. For example, trastuzumab (Herceptin) is only effective in women whose tumours overproduce HER2, while tamoxifen or aromatase inhibitors only work in breast cancer patients with oestrogen receptor-positive tumours. But doctors don’t routinely biopsy metastases, relying on the results of the primary tumour biopsy to guide treatment -- sometimes for many years.

In this study, researchers examined biopsy data from primary breast tumours and liver metastases in 255 women with metastatic breast cancer to determine the status of oestrogen and progesterone receptors and HER2. They found changes in oestrogen receptor status in the secondary tumour in 14.5 percent of women, progesterone status in 48.6 percent and HER2 status in 13.9 percent. This led to changes in therapy in 12.1 percent of the patients.


Source: ASCO

Watch a press briefing from Dr Giuseppe Curigliano on ecancertv here.



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence